TW202523664A - Ahr促效劑 - Google Patents

Ahr促效劑 Download PDF

Info

Publication number
TW202523664A
TW202523664A TW114105013A TW114105013A TW202523664A TW 202523664 A TW202523664 A TW 202523664A TW 114105013 A TW114105013 A TW 114105013A TW 114105013 A TW114105013 A TW 114105013A TW 202523664 A TW202523664 A TW 202523664A
Authority
TW
Taiwan
Prior art keywords
compound
stereoisomer
pharmaceutically acceptable
mixture
formula
Prior art date
Application number
TW114105013A
Other languages
English (en)
Chinese (zh)
Inventor
邁可 奎格瑞 貝爾
雪柔 安 卡森
海因斯 萊希 楚維涅
克里斯 亞歷山大 克拉克
道格拉斯 林 葛那特
史帝芬 詹姆斯 格林
威廉 湯瑪斯 麥克米倫
法蘭克 查爾斯 多西
安東尼奧 那法洛
約翰 羅勃 利梭
喬爾 羅伯特 凱文
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202523664A publication Critical patent/TW202523664A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW114105013A 2022-11-15 2023-11-15 Ahr促效劑 TW202523664A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263425442P 2022-11-15 2022-11-15
US63/425,442 2022-11-15

Publications (1)

Publication Number Publication Date
TW202523664A true TW202523664A (zh) 2025-06-16

Family

ID=89121650

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114105013A TW202523664A (zh) 2022-11-15 2023-11-15 Ahr促效劑
TW112144125A TWI870104B (zh) 2022-11-15 2023-11-15 Ahr促效劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112144125A TWI870104B (zh) 2022-11-15 2023-11-15 Ahr促效劑

Country Status (17)

Country Link
US (1) US20240199608A1 (https=)
EP (1) EP4619401A1 (https=)
JP (2) JP7577819B2 (https=)
KR (1) KR20250083557A (https=)
CN (1) CN120225518A (https=)
AR (1) AR131070A1 (https=)
AU (1) AU2023382389A1 (https=)
CL (1) CL2025001421A1 (https=)
CO (1) CO2025005456A2 (https=)
CR (1) CR20250175A (https=)
DO (1) DOP2025000111A (https=)
IL (1) IL320832A (https=)
JO (1) JOP20250109A1 (https=)
MX (1) MX2025005566A (https=)
PE (1) PE20251588A1 (https=)
TW (2) TW202523664A (https=)
WO (1) WO2024107555A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240124A1 (en) * 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120904199B (zh) * 2025-09-30 2026-03-06 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510528A1 (de) * 1975-03-11 1976-09-23 Hoechst Ag Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
CN1149214C (zh) 1998-12-04 2004-05-12 东丽株式会社 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
ATE463482T1 (de) 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2007506788A (ja) * 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
PL1753427T3 (pl) * 2004-05-28 2008-09-30 Janssen Pharmaceutica Nv Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物
US12312337B2 (en) * 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Also Published As

Publication number Publication date
PE20251588A1 (es) 2025-06-16
KR20250083557A (ko) 2025-06-10
AR131070A1 (es) 2025-02-12
IL320832A (en) 2025-07-01
US20240199608A1 (en) 2024-06-20
JP2025032072A (ja) 2025-03-11
TW202434583A (zh) 2024-09-01
JOP20250109A1 (ar) 2025-05-13
WO2024107555A1 (en) 2024-05-23
CL2025001421A1 (es) 2025-08-18
DOP2025000111A (es) 2025-06-15
EP4619401A1 (en) 2025-09-24
JP7577819B2 (ja) 2024-11-05
AU2023382389A1 (en) 2025-05-15
CN120225518A (zh) 2025-06-27
JP2024072283A (ja) 2024-05-27
CO2025005456A2 (es) 2025-05-19
CR20250175A (es) 2025-05-27
TWI870104B (zh) 2025-01-11
MX2025005566A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
JP6873980B2 (ja) ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
AU2010315126B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP7225251B2 (ja) アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５－テトラヒドロ－２ｈ－ピリド（４，３－ｂ）インドール誘導体
JP5642963B2 (ja) ピリジノニルｐｄｋ１阻害剤
KR102058366B1 (ko) 축합 피리미딘 화합물 또는 그의 염
TWI870104B (zh) Ahr促效劑
JP7073385B2 (ja) タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体
TWI826509B (zh) 作為vanin抑制劑之雜芳族化合物
SG184874A1 (en) Compounds and methods for kinase modulation, and indications therefor
JP2020502252A (ja) Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体
AU2003297565A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
KR20250080854A (ko) Pi3k 억제제로서의 이소퀴놀론
WO2015064714A1 (ja) オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
TW200533656A (en) Therapeutic agents
TW202502751A (zh) Cbl-b抑制劑
WO2024071439A1 (ja) 縮環化合物及びそれを含有する医薬
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
JP2024539213A (ja) アリール又はヘテロアリール誘導体及びこれを有効成分として含むキナーゼ関連疾患の予防又は治療用薬学的組成物
CA3212872A1 (en) Indoline derivatives as ddrs inhibitors
HK40091563A (zh) 嘧啶酮类化合物及其用途
HK40091563B (zh) 嘧啶酮类化合物及其用途
CN118215655A (zh) Ahr激动剂
TW202545947A (zh) 製造１Ｈ—吡唑并［３，４—ｂ］吡化合物之方法
KR20230016190A (ko) Ddr 억제제로서 벤질아민 유도체
TW202602867A (zh) 作為pi3k抑制劑的異喹啉酮